Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Ligand Pharm (LGND)
Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ligand Pharm 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 USA

www.ligand.com P: 858-550-7500

Description:

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. Ligand has merged with CyDex. By this, it added an antibody-generating platform, OmniAb, to the company's portfolio. Its other technology platforms include antigen discovery platform & protein expression platform. All these technologies have created a strong platform for Ligand to seek new licenses and partnerships. Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Celgene, Gilead & Lilly, etc. The company continues to buy smaller companies to increase its technology platforms.

Key Statistics

Overview:

Market Capitalization, $K 1,034,531
Enterprise Value, $K 1,066,221
Shares Outstanding, K 17,355
Annual Sales, $ 196,250 K
Annual Net Income, $ -33,360 K
Last Quarter Sales, $ 32,870 K
Last Quarter Net Income, $ -10,270 K
EBIT, $ 51,580 K
EBITDA, $ 103,700 K
60-Month Beta 0.92
% of Insider Shareholders 10.40%
% of Institutional Shareholders 89.19%
Float, K 15,550
% Float 89.60%
Short Volume Ratio 0.36

Growth:

1-Year Return -12.62%
3-Year Return -35.79%
5-Year Return -56.44%
5-Year Revenue Growth 39.09%
5-Year Earnings Growth -24.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.02 on 11/08/23
Next Earnings Date N/A
Earnings Per Share ttm 3.51
EPS Growth vs. Prev Qtr -35.45%
EPS Growth vs. Prev Year 455.00%
Annual Dividend Yield 0.00%
Most Recent Dividend 2.500 on 04/03/07
Dividend Payable Date 07/01/10
Dividend Payout Ratio 864.09%
Most Recent Split 1-6 on 11/19/10

LGND Ratios

Ratio
Price/Earnings ttm 17.06
Price/Earnings forward 13.95
Price/Earnings to Growth 0.70
Return-on-Equity % 9.67%
Return-on-Assets % 8.03%
Profit Margin % -17.00%
Net Margin % -3.92
Debt/Equity 0.00
Price/Sales 5.29
Price/Cash Flow 11.55
Price/Book 1.53
Book Value/Share 38.47
Interest Coverage 21.01

LGND Dividends

Date Value
04/03/07 $2.5000
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar